CM
XERS icon

Crystalline Management’s Xeris Biopharma Holdings XERS Stock Holding History

Crystalline Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,573
Closed -$36.6K – 98
2024
Q1 		$36.6K Buy
+16,573
New +$42.9K 0.05% 55

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Crystalline Management's XERS Position: Q2 2024 in Review

Crystalline Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2024, closing a stake of 16,573 shares — an estimated $36.6K sold.

Crystalline Management first reported a position in XERS in Q1 2024 and held it in 1 quarter. The position peaked at $36.6K in Q1 2024. 134 funds tracked by Wall St. Rank hold XERS as of Q2 2024.

  • Crystalline Management reported no remaining Xeris Biopharma Holdings position as of Q2 2024 after selling out during the quarter.
  • Crystalline Management sold 16,573 Xeris Biopharma Holdings shares in Q2 2024, an estimated $36.6K.
  • Crystalline Management first reported a position in Xeris Biopharma Holdings in Q1 2024 and held it in 1 quarter.
  • Crystalline Management's Xeris Biopharma Holdings position peaked at $36.6K in Q1 2024.
  • 134 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2024.

Based on Crystalline Management's 13F filing for Q2 2024, filed 8 Aug 2024.